TSHA (Taysha) סך נכסי הפעילות העסקית
Taysha Gene Therapies (TSHA) ensures the continuity of its research through verified biomedical pathways and a network of reliable laboratories. The company relies on advanced gene delivery methods to the brain to combat CNS pathologies. The price action of total assets, reaching 401.91, confirms the business potential. Long-term trials and patent protection transform approved drugs into a stable cash cow for years to come.
פילוחי מדדים פיננסיים ומדדי שוק עבור Taysha (TSHA)
Total assets represent the aggregate resource base of the enterprise, determining its ability to sustain operational activities and investment programs. This metric is reverse-calculated via daily ROA and market capitalization; consequently, the total asset value reacts sharply to changes in the valuation of Taysha Gene Therapies (TSHA) amid clinical trial risks and a liquidity shortage for financing Rett syndrome therapy.